Phase 3 trials of other GLP-1 RAs as well as other classes of medication commonly used in adults (SGLT2 inhibitors and DPP-4 inhibitors) in youth with T2DM are currently ongoing so additional options may be available in the next few years (15). This evidence concerns the gene GCG and type 2 diabetes mellitus.